{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:59:06Z","timestamp":1762549146746,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019393","name":"Relay Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019393","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clbc.2025.04.007","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:12:48Z","timestamp":1744132368000},"page":"e699-e706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium"],"prefix":"10.1016","volume":"25","author":[{"given":"Komal","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carey K.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manali","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Jo","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Krop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany A.","family":"Traina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reva","family":"Basho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison K.","family":"Conlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Esteva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayakrishna","family":"Gadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anya","family":"Litvak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios P.","family":"Mamounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"McCann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahi","family":"Mitri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Shatsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Telli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mylin A.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.04.007_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"year":"2023","series-title":"Cancer Facts & Figures 2023","key":"10.1016\/j.clbc.2025.04.007_bib0002"},{"key":"10.1016\/j.clbc.2025.04.007_bib0003","unstructured":"National Cancer Institute. Surveillance, Epidemiology and End Results Program (SEER). Female breast cancer subtypes\u2014cancer stat facts. Accessed December 12, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html."},{"key":"10.1016\/j.clbc.2025.04.007_bib0004","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0005","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.04.007_bib0006","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0007","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.04.007_bib0008","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0009","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2025.04.007_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"Suppl 7","key":"10.1016\/j.clbc.2025.04.007_bib0011","doi-asserted-by":"crossref","first-page":"S1384","DOI":"10.1016\/j.annonc.2022.08.009","article-title":"MONARCH 3: interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer","volume":"33","author":"Goetz","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0012","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Accordino KA, Chiuzan C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 41(4); LBA1004.","DOI":"10.1200\/JCO.22.02392"},{"issue":"suppl 17","key":"10.1016\/j.clbc.2025.04.007_bib0013","doi-asserted-by":"crossref","first-page":"LBA1001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1001","article-title":"Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4\/6 inhibitor plus endocrine therapy: primary outcome of the phase 3 postMONARCH trial","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0014","article-title":"Imlunestrant with or without Abemaciclib in advanced breast cancer","author":"Jhaveri","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2025.04.007_bib0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/10600280231206131","article-title":"Elacestrant for ER-positive HER2-negative advanced breast cancer","volume":"58","author":"Hageman","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.clbc.2025.04.007_bib0016","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/cancers14020310","article-title":"Role of ctDNA in breast cancer","volume":"14","author":"Sant","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2025.04.007_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clbc.2021.10.007","article-title":"The place of chemotherapy in the evolving treatment landscape for patients with HR-positive\/HER2-negative MBC","volume":"22","author":"Twelves","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.04.007_bib0018","unstructured":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+\/HER2- Early Breast Cancer (NATALEE). Clinicaltrials.gov indentifier: NCT03701334. Updated November 11, 2024. Accessed April 28, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03701334."},{"key":"10.1016\/j.clbc.2025.04.007_bib0019","unstructured":"Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE). Clinicaltrials.gov identifier: NCT03155997. Updated April 20, 2025. Accessed April 28, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03155997."},{"key":"10.1016\/j.clbc.2025.04.007_bib0020","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl 17","key":"10.1016\/j.clbc.2025.04.007_bib0022","doi-asserted-by":"crossref","first-page":"LBA500","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.04.007_bib0023","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.clbc.2025.04.007_bib0024","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clbc.2025.04.007_bib0025","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.04.007_bib0026","series-title":"2023 San Antonio Breast Cancer Symposium. Abstract GS03-13","article-title":"Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis","author":"Jhaveri","year":"2023"},{"key":"10.1016\/j.clbc.2025.04.007_bib0027","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.04.007_bib0028","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.04.007_bib0029","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.04.007_bib0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clbc.2025.04.007_bib0031","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2023.9526","article-title":"Germline genetic testing after cancer diagnosis","volume":"330","author":"Kurian","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2025.04.007_bib0033","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/1758834014539183","article-title":"Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential","volume":"6","author":"Peddi","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.clbc.2025.04.007_bib0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive Human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0036","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.3390\/curroncol30070474","article-title":"Antibody\u2013drug conjugates in breast cancer: ascent to destiny and beyond\u2014a 2023 review","volume":"30","author":"Xiao","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.clbc.2025.04.007_bib0037","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2025.04.007_bib0038","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clbc.2025.04.007_bib0039","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase 2 trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clbc.2025.04.007_bib0041","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.clbc.2025.04.007_bib0042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"Neurorx"},{"key":"10.1016\/j.clbc.2025.04.007_bib0043","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2025.04.007_bib0044","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/cancers14061514","article-title":"Radiotherapy for HER 2 positive brain metastases: urgent need for a paradigm shift","volume":"14","author":"Ippolito","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:56:58Z","timestamp":1762549018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1526820925000989"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.04.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}